Cooperative Agreement U01AI135940

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is funding a $3,356,188 research project titled "IMPACT OF NEONATAL ART AND BROADLY NEUTRALIZING ANTIBODIES ON HIV-1 RESERVOIRS IN INFANTS: TOWARDS ART-FREE REMISSION." The project aims to characterize the HIV-1 proviral pool composition in neonates and infants receiving very early and enhanced early antiretroviral...

This federal Project Grant award of $489,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to improve the targeting and elimination of the intact HIV reservoir. The key products of this 2-year project conducted by The Children's Hospital of Philadelphia Research Institute are: Identifying distinct transcriptional, epigenetic, and clonal features of CD4+ T cells with intact...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,420,190 to the University of California, Davis to understand the reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques. The goal is to investigate the ability of this promising antibody, when given soon after antiretroviral therapy (ART) initiation, to safely deplete the SIV...

This federal Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $113,400 over 5 years to support the development of an HIV cure research program focused on adolescents living with HIV-1 in Botswana. The key objectives are to: 1) identify adolescents with low HIV reservoirs and potential for post-treatment control, 2) evaluate changes in the HIV reservoir over time and enroll eligible participants in an analytical...

This Project Grant award, funded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop ultra-long-acting antiretroviral drug formulations for the treatment of HIV-1 infection in pediatric populations. The $2,207,322 award, effective January 17, 2025 through December 31, 2026, supports an innovative approach to transform established oral pediatric therapies, such as...

This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,332,155 to Emory University to conduct research on virus and host-directed immunotherapies for a cure in SHIV-infected infant macaques. The research objectives are to optimize immunotherapy strategies leveraging three different mechanisms to enhance broadly neutralizing antibodies (BnAbs): 1) reactivating virus...

This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is providing $573,475 to The Botswana Harvard Health Partnership (BHP) to conduct a randomized trial evaluating the effect of integrating sexually transmitted infection (STI) testing with expanded pre-exposure prophylaxis (PrEP) options on PrEP use among pregnant women in Botswana. The study aims to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $647,800.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on quantifying the antiviral activity of antiretroviral therapy (ART) and broadly neutralizing antibodies (bNAbs) during analytic treatment interruption studies for people with HIV. The research aims to 1) understand...

This $756,077 Project Grant was awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports a 5-year research study to investigate the long-term immunologic, cardiovascular, metabolic, and neurocognitive outcomes in children and adolescents with perinatal HIV infection who have achieved viral suppression on long-term antiretroviral therapy. The research will assess...